Researchers found that the new experimental version of interferon beta-1a (used to treat Covid-19) from the British biotechnology company Synairgen increased the chances of improvement and recovery for hospitalized Covid-19 patients in a phase 2 clinical trial.
SNG001 is an inhaled formula of interferon beta-1a, usually used to reduce inflammation and reduce nerve damage caused by multiple sclerosis. In this trial, 48 patients were administered SNG001 using a nebulizer, and 50 patients received a placebo.
Researchers found that after two weeks, patients who received daily treatment were twice as likely to recover on the 15th or 16th day as patients who received placebo, and the likelihood of improvement within 28 days of treatment was to receive More than three times as many placebo patients. However, the researchers wrote: “There was no significant difference in the probability of discharge or time to discharge between the treatment groups.”
Researchers from Synairgen and other institutions found that within two weeks of treatment, 21
Overall, 3 patients died during the study, and all of them belonged to the placebo group.
The researchers also found that by day 16, 11 patients (22%) in the placebo group developed serious illnesses, while 6 patients in the SNG001 group (or 13%).
The most common adverse event in the SNG001 group was headache.
The researchers wrote in the study: “SNG001 is a treatment that has been studied. It is well tolerated by patients with asthma and COPD. It also seems to be well tolerated in hospitalized COVID-19 patients. “These encouraging data provide a strong basis for large-scale international studies in the context of the continuing clinical burden of COVID-19.”
The study has limitations, including the small number of patients in the study.
‘Phase III trials will be required’
He said: “In general, the numbers we are talking about are relatively small. Although there is no signal for discharge or death, there is definitely no motivation.”
Finnigan said: “There must be many different drugs with different delivery mechanisms. There are other inhaled drugs under consideration and research, and they are targeted at different regions.”
He said: “There are antiviral drugs, there are drugs that act on the immune system, antibodies, there are drugs that try to target inflammation, and certain inflammatory mediators.” “In general, unfortunately, it is obtained in this category of patients. The data are largely consistent, and no one other than dexamethasone showed a death benefit.”
When it comes to SNG001, a “larger randomized clinical trial is needed,” Nathan Peiffer-Smadja and Yazdan Yazdanpanah of the Bichat-Claude Bernard Hospital in Paris wrote in an editorial published with the new study in The Lancet Respiratory Medicine.
Peiffer-Smadja and Yazdanpanah wrote: “Since there is no marketing authorization for the nebulization of interferon, the safety of nebulized interferon β-1a will receive special attention.”
They wrote: “It is worthwhile to study whether interferon beta-1a has an effect on long-term COVID-19 symptoms, especially lung symptoms.” “In order to optimize the antiviral effect of interferon beta, there are bigger reasons. For patients in the early stages of the disease.”